生体吸収性スキャフォールドの世界市場分析および予測...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 20
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 23
3 Disease Overview 24
3.1 Coronary Artery Disease 24
3.2 Peripheral Artery Disease 24
3.3 Anatomy and Physiology 25
3.4 Pathophysiology 26
3.4.1 Coronary Artery Disease 26
3.4.2 Peripheral Artery Disease 27
3.5 Clinical Presentation 28
3.5.1 Symptoms of Coronary Artery Disease 28
3.5.2 Symptoms of Peripheral Artery Disease 28
3.6 Risk Factors 29
3.6.1 Coronary Artery Disease 29
3.6.2 Peripheral Artery Disease 29
3.7 Disease Segments 30
3.7.1 Coronary Artery Disease 30
3.7.2 Peripheral Artery Disease 30
3.8 Diagnosis 31
3.8.1 Coronary Artery Disease 31
3.8.2 Peripheral Artery Disease 32
3.9 Clinical Outcomes 33
3.9.1 Treatment Paradigm 33
3.9.2 Treatment Modalities 33
3.9.3 Coronary/Peripheral Artery Bypass Grafting 36
3.9.4 Interventional Cardiology 37
4 Competitive Assessment 42
4.1 Overview 42
4.2 Absorb BVS – Abbott Vascular 43
4.2.1 Efficacy 45
4.3 Remedy – Kyoto Medical Planning 49
4.3.1 Efficacy 51
4.4 DESolve – Elixir Medical Corperation 52
4.4.1 Efficacy 54
4.5 Pure – Arterial Remodeling Technologies 56
4.5.1 Efficacy 57
5 Unmet Needs 59
5.1 Develop a Fully-Bioabsorbable Stent 59
5.2 Reduce the Risk of Complications 59
5.3 Reduce the Need for Stent-in-Stent Procedures 60
5.4 Long-Term Clinical Data 60
5.5 Reduce the Rate of Stent Fracture 61
5.6 Dual Anti-Platelet Therapy 61
5.7 Imaging 61
6 Pipeline Products 62
6.1 Overview 62
6.2 Coronary Artery Disease – Pipeline Products 62
6.2.1 Overview 62
6.2.2 Polymer-Based Bioabsorbable Scaffolds 64
6.2.3 Metallic Bioabsorbable Scaffolds 78
6.2.4 Summary 81
6.3 Peripheral Artery Disease – Peripheral Bioabsorbable Scaffold Product Pipeline 82
6.3.1 Overview 82
6.3.2 Summary 88
7 Industry Overview 90
7.1 Procedure Trends 90
7.1.1 Global Coronary and Peripheral Stenting Procedure Trends 90
7.1.2 Coronary Artery Disease 93
7.1.3 Peripheral Artery Disease 98
8 Market Access 105
8.1 Overview 105
8.2 Regulatory Process 106
8.2.1 United States 106
8.2.2 5EU 107
8.2.3 Asia-Pacific 108
8.2.4 Brazil 111
8.3 Physician Decision-Making Process 112
8.4 Role of Group Purchasing Organizations 114
8.5 Lack of Clinical Data 117
8.6 Regional-Level Control 118
8.7 Cost Considerations 120
8.7.1 United States 120
8.7.2 5EU 121
8.7.3 Asia-Pacific 122
8.7.4 Brazil 123
8.8 Reimbursement Trends 124
8.8.1 United States 124
8.8.2 5EU 125
8.8.3 Asia-Pacific 130
8.8.4 Brazil 133
8.9 Regulatory Issues/Recalls 134
8.10 Product Recalls 134
9 Mergers and Acquisitions 136
9.1 ART and Terumo Corparation 136
9.2 Xenogenics Corporation and Multicell Technologies 136
9.3 Icon Interventional Systems and Ariad Pharmaceuticals 136
9.4 Boston Scientific Corporation 137
10 Current and Future Players 138
10.1 Overview 138
10.2 Trends in Corporate Strategy 138
10.3 Company Profiles 139
10.3.1 Abbott Vascular 139
10.3.2 Kyoto Medical Planning Co., Ltd. 142
10.3.3 Arterial Remodeling Technologies 144
10.3.4 Elixir Medical Corporation 147
10.3.5 Cardionovum 150
10.3.6 Reva Medical 152
10.3.7 OrbusNeich Medical 154
10.3.8 Amaranth Medical 156
10.3.9 Biotronik 158
10.3.10 Lepu Medical Technology 161
10.3.11 HuaAn Biotechnology Co., Ltd. 163
10.3.12 Lifetech Scientific (Shenzhen) Co., LTD. (Lifetech Shenzhen) 165
10.3.13 Arterius 168
10.3.14 S3V Vascular Technologies 169
10.3.15 Tepha Inc. 171
10.3.16 Zorion Medical 173
10.3.17 Xenogenics Corporation 175
10.3.18 Meril Life Sciences 177
10.3.19 Boston Scientific Corporation 179
10.3.20 Icon Interventional Systems 181
11 Market Drivers, Opportunities and Barriers 183
11.1 Market Drivers 183
11.1.1 Rising Prevalence of Disease 183
11.1.2 Avoid Stent-in-Stent Procedures 184
11.1.3 Reduce/Eliminate Dual Anti-Platelet Therapy 185
11.1.4 Availability of Long-Term Data 185
11.1.5 Treatment Considerations 186
11.1.6 Accurate Stent Placement 186
11.1.7 Expected Launch of BAS in the US 187
11.2 Opportunities 187
11.2.1 BAS Segmentation 187
11.2.2 Expanding the Indications for BAS 188
11.2.3 Target High-Risk Patients 189
11.2.4 Improve Deliverability of BAS 190
11.2.5 Emerging Markets 190
11.3 Market Barriers 190
11.3.1 Slow Adoption 190
11.3.2 Complications Associated with BAS 191
11.3.3 High Average Selling Price 192
11.3.4 Reimbursement 193
11.3.5 Substitutes 194
12 Market Outlook and Forecast 196
12.1 Global Market Overview 196
12.2 United States 198
12.2.1 Overview 198
12.2.2 Market Analysis 199
12.3 France 201
12.3.1 Overview 201
12.3.2 Market Analysis 201
12.4 Germany 203
12.4.1 Overview 203
12.4.2 Market Analysis 204
12.5 Italy 206
12.5.1 Overview 206
12.5.2 Market Analysis 206
12.6 Spain 209
12.6.1 Overview 209
12.6.2 Market Analysis 209
12.7 United Kingdom 211
12.7.1 Overview 211
12.7.2 Market Analysis 211
12.8 Japan 213
12.8.1 Overview 213
12.8.2 Market Analysis 213
12.9 Brazil 215
12.9.1 Overview 215
12.9.2 Market Analysis 216
12.10 China 217
12.10.1 Overview 217
12.10.2 Market Analysis 217
12.11 India 220
12.11.1 Overview 220
12.11.2 Market Analysis 220
13 Appendix 223
13.1 Bibliography 223
13.2 Abbreviations 238
13.3 Report Methodology 244
13.3.1 Overview 244
13.3.2 Coverage 244
13.3.3 Secondary Research 244
13.4 Forecasting Methodology 245
13.5 Physicians and Specialists Included in This Study 246
13.6 About the Authors 248
13.6.1 Analysts 248
13.6.2 James Coutcher, Global Head of Healthcare 249
13.7 About GlobalData 250
13.8 Disclaimer 250